Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.

Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K.

J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2305-2312. doi: 10.1111/jdv.15862. Epub 2019 Sep 11.

2.

Perspectives on Living with Chronic Spontaneous Urticaria: From Onset through Diagnosis and Disease Management in the US.

Goldstein S, Eftekhari S, Mitchell L, Winders TA, Kaufman L, Dudas D, Paknis B, Kavati A, Delwart V, Sofen HL.

Acta Derm Venereol. 2019 Nov 1;99(12):1091-1098. doi: 10.2340/00015555-3282.

3.

Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor.

Gooderham M, Elewski BE, Pariser DM, Sofen H, Mendelsohn AM, Rozzo SJ, Li Q.

J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e350-e352. doi: 10.1111/jdv.15643. Epub 2019 May 8. No abstract available.

4.

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E.

Br J Dermatol. 2019 Oct;181(4):733-742. doi: 10.1111/bjd.17932. Epub 2019 May 6.

5.

Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.

Wang Y, Coyne K, Sofen H, Santanello N, Currie B, Zhang Z, Nograles K.

J Dermatolog Treat. 2019 Dec;30(8):775-783. doi: 10.1080/09546634.2019.1577546. Epub 2019 Mar 5.

PMID:
30747550
6.

"A Reliability Study Using Network-Oriented Research Assistant (NORA®) to Evaluate the Use of Digital Photographs in the Assessment of Atopic Dermatitis".

Hughes ME, Aralis H, Bruhn KW, Cotliar J, Craft N, DeLuca IJ, Hamidi R, Nguyen K, Patel M, Patel VA, Sofen H, Tan BH, David CV.

J Am Acad Dermatol. 2019 Jan 28. pii: S0190-9622(19)30150-1. doi: 10.1016/j.jaad.2019.01.043. [Epub ahead of print] No abstract available.

PMID:
30703454
7.

A reliability study using Network Oriented Research Assistant (NORA® ) examining the use of digital photographs in the assessment of psoriasis.

Jeong D, Aralis H, Bruhn KW, Cotliar J, Craft N, DeLuca IJ, Hamidi R, Nguyen K, Patel VA, Sofen H, Tan BH, David CV.

Br J Dermatol. 2019 Jul;181(1):214-215. doi: 10.1111/bjd.17702. Epub 2019 Mar 19. No abstract available.

PMID:
30703265
8.

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials.

Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M.

J Am Assoc Nurse Pract. 2018 Sep;30(9):529-541. doi: 10.1097/JXX.0000000000000088.

PMID:
30211823
9.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.

Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.

PMID:
30097359
10.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).

Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M.

J Am Acad Dermatol. 2018 Aug;79(2):266-276.e5. doi: 10.1016/j.jaad.2018.04.013. Epub 2018 Apr 14.

11.

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, Owen R, Putnam W, Castro M, DeBusk K, Lin CY, Voulgari A, Yen K, Omachi TA.

J Am Acad Dermatol. 2018 May;78(5):863-871.e11. doi: 10.1016/j.jaad.2018.01.017. Epub 2018 Jan 17.

12.

Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.

Casale TB, Win PH, Bernstein JA, Rosén K, Holden M, Iqbal A, Trzaskoma BL, Yang M, Antonova EN, Murphy T, Scarupa MD, Sofen H, Kaplan A.

J Am Acad Dermatol. 2018 Apr;78(4):793-795. doi: 10.1016/j.jaad.2017.10.010. Epub 2017 Oct 14. No abstract available.

13.

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials.

Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):68-72. doi: 10.1111/jdv.14581. Epub 2017 Oct 6.

PMID:
28881462
14.

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1693-1699. doi: 10.1111/jdv.14391. Epub 2017 Aug 8.

15.

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.

Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A.

Adv Ther. 2017 Jul;34(7):1772. doi: 10.1007/s12325-017-0563-2. No abstract available.

16.

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.

Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P.

J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4.

PMID:
28573743
17.

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ.

N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.

18.

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.

Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A.

Adv Ther. 2017 Jun;34(6):1327-1339. doi: 10.1007/s12325-017-0521-z. Epub 2017 Apr 10. Erratum in: Adv Ther. 2017 Jul;34(7):1772.

19.

Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.

Leonardi CL, Blauvelt A, Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1483-1490. doi: 10.1111/jdv.14211. Epub 2017 Jun 28.

PMID:
28294430
20.

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31. Erratum in: J Eur Acad Dermatol Venereol. 2017 Oct;31(10 ):1764.

Supplemental Content

Loading ...
Support Center